コンテンツにジャンプ
研究所ロゴ

トップページ > 研究組織一覧 > 分野・独立ユニットグループ > 分子診断・個別化医療開発グループ > がんゲノミクス研究分野 > 論文業績

論文業績

  1. Jusakul A, Totoki Y, Nakamura H, Shibata T, et al. Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma. Cancer Discovery, 2017, in press.
  2. Chaisaingmongkol J, Hama N, Shibata T, et al. Common molecular subtypes among Asian hepatocellular and cholangiocarcinoma. Cancer Cell, 2017, in press.
  3. Cancer Genome Atlas Research Network. Comprehensive and integrative genomic characterization of hepatocellular carcinoma. Cell, 2017;169:1327-1341. PMID: 28622513
  4. Ogura K, Hosoda F, Nakamura H, Hama N, Totoki Y, Yoshida A, Ohashi S, Rokutan H, Takai E, Yachida S, Shibata T, et al. Highly recurrent H3F3A mutation with additional epigenetic regulator alterations in giant cell tumor of bone. Genes, Chromosome and Cancer, 2017, in press. PMID: 28545165
  5. Alexandrov, LB, Totoki Y, Shibata T, et al. Mutational signatures associated with tobacco smoking in human cancer. Science, 2016, 354:618-622. PMID: 27811275
  6. Nishimoto Y, Shibata T, et al. High stability of faecal microbiome composition in guanidine thiocyanate solution at room temperature and robustness during colonoscopy. Gut. 2016;65(9):1574-5. PMID: 27340192
  7. Rokutan H, Hosoda F, Hama N, Nakamura H, Totoki Y, Arakawa E, Ohashi S, Urushidate T, Shimizu H, Igarashi K, Yachida S, Shibata T, et al. Comprehensive mutation profiling of mucinous gastric carcinoma. J Pathol. 2016;240(2):137-48. PMID: 27313181
  8. Kataoka K, Totoki Y, Shibata T, et al Aberrant PD-L1 expression via 3’-UTR disruption in multiple cancers. Nature 2016;534:402-6. PMID: 27281199
  9. Fujimoto A, Totoki Y, Nakamura H, Hama N, Hosoda F, Arai Y, Ohashi S, Urushidate T, Shibata T, et al. Whole genome mutational landscape and characterization of non-coding and structural mutations in liver cancer. Nat Genet, 2016;48:500-9. PMID: 27064257
  10. Satoh H, Shibata T, et al. NRF2 intensifies host defense systems to prevent lung carcinogenesis, but after tumor initiation accelerates malignant cell growth. Cancer Res, 2016; 76(10):3088-96. PMID: 27020858
  11. Yachida S, Totoki Y, Arai Y, Nakamura H, Hama N, Shibata T, et al. Genomic sequencing identifies ELF3 as a driver of ampullary carcinoma. Cancer Cell, 2016, 29:229-40. PMID: 26806338
  12. Kataoka K, Totoki Y, Shibata T, et al Integrated molecular analysis of adult T cell leukemia/lymphoma. Nat Genet. 2015 47:1304-15.
  13. Nakamura H, Arai Y, Totoki Y, Shirota T, Hama N, Hosoda F, Urushidate T, Ohashi S, Shibata T, et al. Genomic spectra of biliary tract cancer. Nat Genet, 2015, 47:1003-10. PMID: 26437031
  14. Creixell P, Shibata T, et al. Pathway and network analysis of cancer genomes. Nat Methods. 2015 12:615-21. PMID: 26125594
  15. Totoki Y, Nakamura H, Hama N, Hosoda F, Arai Y, Urushidate T, Ohashi S, Okada N, Shibata T, et al. Trans-ancestry mutational landscape of hepatocellular carcinoma genomes. Nat Genet, 2014, 46:1267-73. PMID: 25362482
  16. Totoki Y, Hosoda F, Nakamura H, Hama N, Ogura K, Arai Y, Shibata T, et al. Unique mutation portraits and frequent COL2A1 gene alteration in chondrosarcoma. Genome Res, 2014 24:1411-20. PMID: 25024164
  17. Shibata T, et al. Exploration of liver cancer genomes. Nat Rev Gastroenterol Hepatol., 2014, 11:340-9. PMID: 24473361
  18. Arai Y, Tototki Y, Hosoda F, Shirota T, Hama N, Nakamura H, Shibata T, et al. FGFR2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatology, 2014, 59:1427-34.
  19. Alexandrov LB, Shibata T, et al. Signatures of mutational processes in human cancer. Nature, 2013 500:415-21. PMID: 24122810
  20. Gonzalez-Perez A, Shibata T, et al. Computational approaches to identify functional genetic variants in cancer genomes. Nat Methods, 2013, 10:723-9. PMID: 23900255
  21. Mitsuishi Y, Shibata T, et al. Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. Cancer Cell, 2012, Jul 10;22(1):66-79. PMID: 22789539
  22. Fujimoto A, Totoki Y, Hosoda F, Arai Y, Shirakihara T, Nakamura H, Shibata T, et al. Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat Genet, 2012;44(7):760-4. PMID: 22634756
  23. Kohno T, Shibata T, et al. KIF5B-RET fusions in lung adenocarcinoma. Nat Med, 2012 Feb 12;18(3):375-7. PMID: 22327624
  24. Totoki Y, Arai Y, Hosoda F, Shibata T, et al. High-resolution characterization of a hepatocellular carcinoma genome. Nat Genet, 2011, 43, 464-469. PMID: 21499249
  25. The International Cancer Genome Consortium. International network of cancer genome projects. Nature. 2010, 464:993-998. PMID: 20393554
  26. Shibata T, Kokubu A, et al. Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer. Gastroenterology. 2008, 135:1358-1368. PMID: 18692501
  27. Shibata T, Kokubu A, et al. Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promotes malignancy. Proc Natl Acad Sci USA. 2008, 105:13568-73. PMID: 18757741
  28. Katoh H, Hosoda F, Shibata T, et al. Genetically distinct and clinically relevant classification of hepatocellular carcinoma. Gastroenterology, 2007, 133, 1475-1486. PMID: 17983802